Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 418

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 418
---
 three years that were not registered under the Securities
Act of 1933, as amended. Unless otherwise indicated below, the issuance of such shares was deemed exempt from registration requirements
of the Securities Act, of 1933, as amended, as such securities were offered and sold outside of the United States to persons who were
neither citizens nor residents of the United States, pursuant to Regulation S, or such sales were exempt from registration under Section
4(2) of Securities Act of 1933, as amended and Rule 506 of Regulation D promulgated thereunder.

On February 15, 2023, we completed the closing of a private placement pursuant to which we sold to certain institutional investors (1) 3,250,000 Ordinary Shares represented by 325 Depositary Shares at $4,640.00 per Depositary Share, (2) 12,931,020 Ordinary Shares represented by 1,293 Depositary Shares, issuable upon the exercise of Series A Warrants issued in the private placement at an exercise price of $5,360.00 per warrant, (3) 19,396,400 Ordinary Shares represented by 1,939 Depositary Shares, issuable upon the exercise of Series B Warrants issued in the private placement at an exercise price of $5,360.00 per warrant, and (4) 62,184,525 Ordinary Shares represented by 6,218 Depositary Shares, issuable upon the exercise of pre-funded warrants issued in the private placement at an exercise price of $0.80 per warrant, for aggregate gross proceeds of approximately $6.0 million. We also issued unregistered placement agent warrants to purchase a total of 536,800 Ordinary Shares represented by 52 Depositary Shares toLadenburg Thalman & Co. Inc. at an exercise price of $10,000.00 per warrant for one warrants and an exercise price of $5,800.00 per warrant for 51 warrants, and Series A Warrants to purchase 625,000 Ordinary Shares represented by 62Depositary Shares at an exercise price of $5,360.00 per warrant to an investor pursuant to a waiver.

| II-1 |

On
May 26, 2023, we completed the closing of the May 2023 Registered Direct Offering, with institutional investors of (1) 166,017,700 Ordinary
Shares represented by 16,601 Depositary Shares, issuable upon the exercise of the Series C W